公开(公告)号：US20200276302A1

公开(公告)日：2020-09-03

申请号：US16870354

申请日：2020-05-08

Applicant: OSAKA UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Atsushi Kumanogoh ,  Ryusuke Omiya ,  Hiroyuki Tsunoda ,  Takeshi Baba ,  Sachiyo Suzuki ,  Yuri Teranishi

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/46 ,  C12N15/09

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

公开(公告)号：US20190119747A1

公开(公告)日：2019-04-25

申请号：US16089317

申请日：2017-03-28

Applicant: Osaka University

Inventor： Kohji Nishida ,  Atsushi Kumanogoh ,  Noriyasu Hashida

IPC: C12Q1/6876

Abstract: The principal purpose of the present invention is to provide a novel stress biomarker that makes it possible to conveniently and accurately assess a state of stress. In addition, the present invention provides a diagnosis kit containing a reagent capable of detecting said biomarker, and a diagnosis method that uses said biomarker. It is possible to use mitochondrial DNA included in a biological fluid as the stress biomarker.

公开(公告)号：US20230357390A1

公开(公告)日：2023-11-09

申请号：US18356489

申请日：2023-07-21

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh

IPC: C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62

CPC classification number: C07K16/28 ,  C07K16/3061 ,  C07K16/2896 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62 ,  C07K2317/734 ,  C07K2317/34 ,  C07K2317/33 ,  A61K2039/505

Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

公开(公告)号：US11576969B2

公开(公告)日：2023-02-14

申请号：US16870354

申请日：2020-05-08

Applicant: OSAKA UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Atsushi Kumanogoh ,  Ryusuke Omiya ,  Hiroyuki Tsunoda ,  Takeshi Baba ,  Sachiyo Suzuki ,  Yuri Teranishi

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/46 ,  C12N15/09

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

公开(公告)号：US10988540B2

公开(公告)日：2021-04-27

申请号：US16905211

申请日：2020-06-18

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh ,  Junichi Takagi

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00 ,  C07K16/30

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US10794907B2

公开(公告)日：2020-10-06

申请号：US14258617

申请日：2014-04-22

Applicant: OSAKA UNIVERSITY

Inventor： Atsushi Kumanogoh

IPC: G01N33/53 ,  G01N33/566 ,  C07K16/18 ,  C07K16/28

Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

公开(公告)号：US10688178B2

公开(公告)日：2020-06-23

申请号：US15741225

申请日：2016-06-30

Applicant: OSAKA UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Atsushi Kumanogoh ,  Ryusuke Omiya ,  Hiroyuki Tsunoda ,  Takeshi Baba ,  Sachiyo Suzuki ,  Yuri Teranishi

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/46 ,  C12N15/09

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

公开(公告)号：US20200270686A1

公开(公告)日：2020-08-27

申请号：US16089114

申请日：2017-03-28

Applicant: Osaka University

Inventor： Kohji Nishida ,  Atsushi Kumanogoh ,  Noriyasu Hashida

IPC: C12Q1/6883

Abstract: The principal purpose of the present invention is to provide a biomarker that makes it possible to conveniently and accurately assess corneal or conjunctival disease, and can use lacrimal fluid as the sample thereof. In addition, a main object of the present invention is to provide a biomarker that makes it possible to conveniently and accurately evaluate central serous chorioretinopathy. The present invention also provides a diagnostic kit containing a reagent capable of detecting the biomarker, and a diagnosis method that uses the biomarker. It is possible to use mitochondrial DNA included in lacrimal fluid as the biomarker for corneal or conjunctival disease.

公开(公告)号：US10654931B2

公开(公告)日：2020-05-19

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh ,  Junichi Takagi

IPC: C07K16/28 ,  A61K39/00 ,  C07K19/00 ,  C12N5/10 ,  C12N5/09 ,  A61K35/17 ,  C12N15/09 ,  A61P35/00 ,  C07K16/30

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.